Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCDXS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļCodexis Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 22, 2010
āļāļĩāļāļĩāđāļMoore (Alison)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ188
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļApr 22
āļāļĩāđāļāļĒāļđāđ200 Penobscot Dr
āđāļĄāļ·āļāļREDWOOD CITY
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94063
āđāļāļĢāļĻāļąāļāļāđ16504218100
āđāļ§āđāļāđāļāļāđhttps://www.codexis.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCDXS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 22, 2010
āļāļĩāļāļĩāđāļMoore (Alison)
Mr. David V. Smith
Lead Independent Director
Lead Independent Director
Dr. Alison Moore, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Kevin Norrett
Chief Operating Officer
Mr. Dennis P. Wolf
Independent Director
Dr. Rahul Singhvi
Independent Director
Dr. Esther Martinborough, Ph.D.
Dr. Esther Martinborough, Ph.D.
Independent Director
Ms. Cynthia Collins
Independent Director
Dr. Raymond De Vre, Ph.D.
Dr. Raymond De Vre, Ph.D.
Independent Director
Mr. Christos Richards
Independent Director
Ms. Georgia L. Erbez
Chief Financial Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. David V. Smith
Lead Independent Director
Lead Independent Director
Dr. Alison Moore, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Kevin Norrett
Chief Operating Officer
Mr. Dennis P. Wolf
Independent Director
Dr. Rahul Singhvi
Independent Director
Dr. Esther Martinborough, Ph.D.
Dr. Esther Martinborough, Ph.D.
Independent Director
Invesco NASDAQ Future Gen 200 ETF
Invesco Nasdaq Biotechnology ETF
Fidelity Enhanced Small Cap ETF
iShares Biotechnology ETF
ProShares Ultra Nasdaq Biotechnology
Global X Russell 2000 ETF
Invesco RAFI US 1500 Small-Mid ETF
Proshares Ultra Russell 2000
iShares Russell 2000 Growth ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco NASDAQ Future Gen 200 ETF
āļŠāļąāļāļŠāđāļ§āļ0.47%
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
Fidelity Enhanced Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.02%
Global X Russell 2000 ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
Invesco RAFI US 1500 Small-Mid ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
Proshares Ultra Russell 2000
āļŠāļąāļāļŠāđāļ§āļ0.01%
iShares Russell 2000 Growth ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ